Friday, June 1st, 2018, Baltimore, MD – Insilico Medicine, a Baltimore-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, today announced the participation and presentations of Polina Mamoshina, Sr Research Scientist in Pharma.AI Division of Insilico Medicine, and Lucy Ojomoko, Blockchain AI Program Manager in Insilico Medicine, at the CogX 2018 Conference, June 11-12, London, UK.
Polina Mamoshina will take part in the session titled "Is Artificially Extending Life Intelligent?" alongside Gregory Bailey, CEO of Juvenescence AI. The session and talks will cover the latest advances in AI intended to transform the pharmaceutical and healthcare industry, increase lifespan and productive longevity. Lucy Ojomoko will take part in the session titled "Research, Healthcare, and Medical Records: the Case for Blockchain". Together with Kamal Obbad, the CEO and co-founder of Nebula Genomics she will present the recent application of blockchain technology for healthcare and drug discovery.
"We are very happy to present at the CogX 2018, which gathers the many scientists and companies working on AI. The topic of AI and Blockchain for healthcare is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
CogX is an annual festival gathering leading experts in AI, Blockchain and Emerging Technologies. The event brings together 4,000 attendees and 300 speakers to explore how AI intersects with Emerging Technologies including Blockchain, IoT and 5G telecoms, VR and AR, as well as the future of transportation, health and education.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
###
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
[email protected]
Website: insilico.com
Official Conference Website:
https://cogx.co
About Insilico Medicine, Inc
Insilico Medicine, Inc. is developing the next-generation artificial intelligence for the integrated end-to-end pharmaceutical biomarker development, target identification, small molecule generation and prediction of the clinical trials outcomes. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.
Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI.
Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
Media Contact
Qingsong Zhu
[email protected]
443-451-7212
@InSilicoMeds
http://www.insilicomedicine.com
